Healthy Returns: Identifying Future Winners Amid Rapid Medical Innovation

episode

The Outthinking Investor with Daleep Singh not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from The Outthinking Investor with Daleep Singh

Chip Craze: Framing Industrial Policy for the AI Era 37 min · 11 Aug 2026

The Power Play: Is Fusion Nearing a Kitty Hawk Moment? 23 min · 20 Jul 2026

Warsh's Opening Act: Inside the Fed's Regime Shift with James Bullard 23 min · 07 Jul 2026

Strategic Stalemate: What Investors Miss About U.S.-China Competition 37 min · 08 Jun 2026

All episodes from The Outthinking Investor with Daleep Singh →

Report any issue

Source

Recorded19 Mar 2024

Publisherblm5757040378.libsyn.com ↗

Handlerec:5525372

Show notes

Some medical breakthroughs come from unexpected sources. The origins of new weight-loss drugs such as Ozempic—known in the industry as GLP-1s—can be traced back to 2005, when they were introduced as a treatment for diabetes. Two decades later, these drugs have seemingly burst onto the medical scene, gaining notoriety for their ability to help people lose weight and the potential implications for a variety of other business sectors. This "Ozempic effect" serves as an important lesson for investors: Healthcare innovations often have a cascading impact on the economy and their portfolios. With the healthcare industry working overtime on the next big breakthrough, identifying future winners in the medical field will lead investors to new opportunities. The Outthinking Investor gathered insights from experts in the healthcare space to dig deeper into the future of medical innovations and how consumer behavior could change with the rise of weight-loss drugs. Our guests in this episode are Daniel Matviyenko, Managing Director and Portfolio Manager for Jennison's healthcare strategies; Scott Swanson, Principal and Credit Analyst at PGIM Fixed Income; and Tim Dall, a health economist and Executive Director at GlobalData.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.